Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OPA-DC
- Development stage
- Unknown
- Lead developer
- Mie University
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intradermal
01
Overview
OPA-DC is an autologous dendritic cell (DC) vaccine investigated for the treatment of advanced colorectal cancer (CRC). The vaccine is composed of mature dendritic cells loaded with carcinoembryonic antigen (CEA) peptides. The maturation process utilizes a specific cocktail abbreviated as OPA, which consists of OK432 (a lyophilized preparation of Streptococcus pyogenes), a prostanoid (typically prostaglandin E2), and interferon-alpha (IFN-α). This combination is designed to rapidly generate highly potent, mature DCs capable of inducing robust CEA-specific cytotoxic T lymphocyte (CTL) responses and enhancing natural killer (NK) cell activity. Clinical studies have demonstrated that the vaccine is well-tolerated and can stimulate immune responses, although clinical efficacy as a monotherapy in advanced disease has been limited, suggesting a need for additional modulation to achieve significant clinical impact.
- Other names
- CEA peptide-loaded OPA-DC vaccineOK432-prostanoid-IFN-alpha-matured dendritic cell vaccineOK-432-prostanoid-IFN-alpha-matured dendritic cell vaccineOK 432-prostanoid-IFN-alpha-matured dendritic cell vaccine
Beyond the preview
Go deeper on OPA-DC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OPA-DC.